Journal Article Review Epublish
PubMed: 39469411 DOI: 10.7759/cureus.70312
Recent Advances in the Development and Utilization of Nanoparticles for the Management of Malignant Solid Tumors.
Cureus 16(9):e70312
Authors: Dhanashri D Chavan, Rohit R Bhosale, Vandana M Thorat, Amol S Shete, Sarika J Patil, Devkumar D Tiwari
Affiliations
- Department of Pharmacology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth (Deemed to be University), Malkapur, IND.
- Department of Pharmaceutics, Krishna Foundation's Jaywant Institute of Pharmacy, Wathar, IND.
- Department of Pharmaceutics, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Malkapur, IND.
Abstract
The purpose of nanotechnology-based drug delivery systems or novel drug delivery systems is to improve the effectiveness of therapy, and their promising properties have led to their increasing significance in the management of cancer. The researchers have primarily focused on designing novel nanocarriers, like nanoparticles (NPs), that can effectively deliver drugs to target cells and respond specifically to conditions particular to cancer. Whether passive or active targeting, these nanocarriers can deliver therapeutic cargoes to the tumor site to release the drug from the drug delivery systems. The purpose of this study is to provide recent scientific literature and key findings to researchers as well as the scientific community from the medical and pharmaceutical domains by reporting current advancements in the development of NPs for the treatment of different malignant solid tumors, such as colorectal, pancreatic, prostate, and cervical cancer.
MeSH
Nanoparticles, Pharmaceutical Preparations, Neoplasms, Drug Delivery Systems, Therapeutics, Nanotechnology